6.30
-0.03(-0.47%)
Currency In USD
| Previous Close | 6.33 |
| Open | 6.29 |
| Day High | 6.37 |
| Day Low | 6.09 |
| 52-Week High | 17.83 |
| 52-Week Low | 3.76 |
| Volume | 1.05M |
| Average Volume | 1.31M |
| Market Cap | 587.19M |
| PE | -1.45 |
| EPS | -4.35 |
| Moving Average 50 Days | 7.51 |
| Moving Average 200 Days | 7.47 |
| Change | -0.03 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $142.79 as of November 09, 2025 at a share price of $6.3. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $370.59 as of November 09, 2025 at a share price of $6.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
GlobeNewswire Inc.
Nov 06, 2025 1:30 PM GMT
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and repr
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
GlobeNewswire Inc.
Oct 31, 2025 1:05 PM GMT
Faster initial remission and response, persistent benefit over six monthsSALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a pos
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
GlobeNewswire Inc.
Oct 27, 2025 8:15 PM GMT
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025